《NCCN临床实践指南:非小细胞肺癌(2020V6)》由会员分享,可在线阅读,更多相关《NCCN临床实践指南:非小细胞肺癌(2020V6)(7页珍藏版)》请在金锄头文库上搜索。
1、NCCN临床实践指南汨非小细胞肺癌(2020.V6 ) 要点NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines3Non-Small Cell LungCancerVersion 2 .2020 December 23, 2019NCCN.org2019年12月,美国国家综合癌症网络(NCCN)发布了非小细胞肺癌(NSCLC)指南2020年第2版,相对于2019版,新版指南系统性治 疗方面又有哪些变化呢?让我们一探究竟。1、靶向治疗EGFR突变阳性患者的一线治疗(NSCLC-19)Thraigy fIMSGLQtHElrr
2、wrlini沪category * prflresE,w1Ertq|inibpp (cvVvgorv 1 or Affaftinlb11Of QfltinlbP*1 grssioniSee SiJbMquflinl:Ttiri |NSCL2pF仙令理口uirnt Tharapy 氓轨:LG和k 泡 PT町肓 M 袖daila耳叱 BoqijTKtif 帥冊帼is fiN9CL0).0讯 Mratiteii EE=rapY 心.3阳佃甜 o制匕塗就匕 Dsassa INSCLJIuPF Far pcrlzirnancE!- AIajx 0-4.柬 IF sysiftmcc ihwapy Rrgi
3、TBsn snfnind; Jin irrmure? di-ffrkFoinl rikitafasr. physkian* 卡hcmlH het await erf ffir long hnIL山ft cJ such dnj申 and 悶In reading adwM: evftfits wTian coaibinlngi ehsckpoinc inNbUarB Hti CBfnerGr. SctioerTeti AJS Artour KGB Riz/i H., ei 3l. Septra- inmune-fetai&devenne areKHmusn 罰tiPtl-(L1 blm*曲科 hi
4、iJ bs-i7iwtint!. Ari仃 g出巫山玄側:的亠B4 Oslvrna Y, Taiiindlc 7, 丫磚 艮 Tbja A EGFR-TKJMBauEiated iribfiabtKdJ pntuirKMiiii ii riR/luniafe- twated paiienh with nofi-smaN odl kmg GanGerALIA Onffil 204 1112-1115; Ahn Md Ying J, Yu Hi el d Ds merlin beam bi ne d wth durviijmab in EGFR-muhrtl flan-iraH cell lurg
5、 cancsr: rjuIb from tw TATTON phssa ib Inal. J Thorac Onwl 2Q-1t.11:$1l&fEt!, Cilte個 for IrefllrerM #ti BwaoiZKnafr: no-squafmxjB NSCLC sndl no 临cent hislary af liernoptjaj&蚩站 FCpprqvcd &KJ5m|gF 15. gn flporgprK? SUftSliMc M bwiCEurrflb,(2020.V2)新增:厄洛替尼+雷莫芦单抗作为“其他推荐”治疗方案,属于 2A类。厄 洛替尼+贝伐珠单抗作为“特殊情况下有用
6、”的治疗选择,属于2B类。(2020.V1)新增了一条关于系统性治疗的脚注说明:如果系统性治疗方案中包含免疫检查点抑制剂,则医生应注意此类药物的半衰期较长,并且当将检查点抑制剂与奥西替尼联合使用时应报告不良事件的数据。奥西替尼治疗中进展的后续治疗(NSCLC-20 ) ConodedeflnMve local therapy SABR or curgry) for limited 归石ion評Brain *SmptDfnBlic ContinueProgre&slcn, bbs therapy11* (crviiiulEliple laslon, neted below Consjder do
7、ilnitilve local thefap SHSF f-Consjdfir deflnfive local tharapy (eg, SABR or surgerye ConttnuB wlrueriiniborB Sw subsequent thieiinapy for muhiple lesions,帕啲 belowSea Initial sy&Lernicoptions*4*Squamans Cell.CrciTOmaJ* lnijerguidi iFleiirwl 方陽Huri iu- dn4jptO1 fbi se*K;ltfd泌也=i Ssi!凤叩伫/比勺凹 时”电o商 出町.
8、削可!N-SGL-GJ-5己己 Tari*5lBi TiesiBpy口r MYrHnc皀d 口10&巫己hfiULNl.1nf phrnnrn?non in ;utisei qi pntKinls who rincLiritinu E右FFt IWl If 日加he flare dccij. nfttari EGFfl TKI* Consider a bicris nA time * pusgre-KXinn In Me 口皿 SCLC 也 JwTnmi&icri、AtjGffitj * uKimn应 mfljf tw 心ansi伽rd in patenigdtsetse: Drpgncsgj
9、-cri ci EG FR TKi Ehoragy* The 曲5 in the Mnr-linc- 5eBng suggwl th刖 PD-1 |PD4J 冰 hclqi mgnqhcrsipy 詬 lew cffdrvp. iiTrspecliv?- rf PO-Ll 卵pnwsim ir EQFR皿U4 N$XC(2020.V1)对于有症状的多发病灶,新增1条脚注说明:在进展时考虑进行活检以 排除SCLC转化。厄洛替尼、阿法替尼、吉非替尼或达克替尼治疗中进展的后续治疗(NSCLC-21 )ArThpkHYiatlc-ramu 匚lLm;i口 . ar dacamJ-HnlbH-Con&K
10、ler da-finive local therapy (eg, SAfilR & surgory) tor II mtted” QsInwrEJnl 13(11 T79D秸料匚打*gory 1|igrCanUnuu crloUnl H frnuel rumsb or Emvsctzu orafatln血gefltlnlbar dacomrunlb Consider de41nftlv& local mrapy (eg, 3RS) brIf pmgrosslon rg口 |lN5CL-2C;ProgrBssl on, sad hrapy啊* ligr miiltJple les-lonB. f
11、lowd b6kwCantinLM crlllrii b iwnui rurab or 蓟从曲亡阪m由 or ar-atlnlbw gentlnlbof dacomltJnlb11-麻也斛(州0口阳|締6忌fChTiW吕匚 Gonslder deHniUve1 locl Ih&rapy (eg,吕悶 R or supgerylTa 亡口 rrilnuo orl 口 tinlb 1 ramuclrurnjib ar liM vac I z*u ma bl or afjtlnlb or gefltlnlb or dJicnh:lnibIf progrosalion, fan- N$CL-2p) t
12、f prograssKin. sce 111。2呻刊* tar multiply fifllcT 口gJg*ForniijgiJp層 iMlon呂 belowtf progresskin. see Iwrsg甲刊tor muhiph 加lcm. nowd belowSilFiJliafl i&ysliifnic Itierapy optlonfi*1 口ESiEinixr.gi 问Sif Ior iilBMn口HS 屉I 0电FPirngTHYN&tLrjl I阿 ForpflisUiLuhCH.rtBna iv Ir-MlmHil bevacuumgb rwn-K|mrTWUQ- nSClC. am# nohistory d fwmoptynis11 Be*rc 打帘砂 Renomenoi r EdbKl of palBU-K+ N5CLCMkhuld bA 砂曲二! * 越些1 百阳i&i 5 ERR TKH.巾f EhA TTM MiXdiWi II plriAriU-bAid &巧 tfi r刪pliM; IiMuA4lAAMI.th 閹t琴AyE南唱 埠pUpngl-f喲:4ynm